CN115667238A - 一种五并五元环衍生物及其在医药上的应用 - Google Patents

一种五并五元环衍生物及其在医药上的应用 Download PDF

Info

Publication number
CN115667238A
CN115667238A CN202180036568.7A CN202180036568A CN115667238A CN 115667238 A CN115667238 A CN 115667238A CN 202180036568 A CN202180036568 A CN 202180036568A CN 115667238 A CN115667238 A CN 115667238A
Authority
CN
China
Prior art keywords
ring
substituted
methyl
alkoxy
optionally further
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180036568.7A
Other languages
English (en)
Other versions
CN115667238B (zh
Inventor
张晨
雷鸣
赵明亮
余彦
唐平明
翁光林
牟韬
李瑶
倪佳
严庞科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tibet Haisike Pharmaceutical Co ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of CN115667238A publication Critical patent/CN115667238A/zh
Application granted granted Critical
Publication of CN115667238B publication Critical patent/CN115667238B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

一种通式(I)所述的化合物或者其立体异构体、互变异构体、氘代物、溶剂化物、前药、代谢产物、药学上可接受的盐或共晶，及其中间体和制备方法，以及在制备治疗与糖尿病的药物中的应用。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202180036568.7A 2020-12-25 2021-12-24 一种五并五元环衍生物及其在医药上的应用 Active CN115667238B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2020115572973 2020-12-25
CN202011557297 2020-12-25
CN202110109531 2021-01-27
CN2021101095314 2021-01-27
CN2021104033659 2021-04-16
CN202110403365 2021-04-16
CN2021110001759 2021-09-02
CN202111000175 2021-09-02
PCT/CN2021/141243 WO2022135572A1 (zh) 2020-12-25 2021-12-24 一种五并五元环衍生物及其在医药上的应用

Publications (2)

Publication Number Publication Date
CN115667238A true CN115667238A (zh) 2023-01-31
CN115667238B CN115667238B (zh) 2024-08-23

Family

ID=82158827

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180036568.7A Active CN115667238B (zh) 2020-12-25 2021-12-24 一种五并五元环衍生物及其在医药上的应用

Country Status (10)

Country Link
US (1) US20240124470A1 (zh)
EP (1) EP4269399A4 (zh)
JP (1) JP2024500949A (zh)
KR (1) KR20230124956A (zh)
CN (1) CN115667238B (zh)
AU (1) AU2021405918A1 (zh)
MX (1) MX2023007569A (zh)
TW (1) TW202233181A (zh)
WO (1) WO2022135572A1 (zh)
ZA (1) ZA202306652B (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116323599A (zh) 2020-08-06 2023-06-23 加舒布鲁姆生物公司 杂环glp-1激动剂
EP4204415A1 (en) 2020-08-28 2023-07-05 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2023025201A1 (zh) * 2021-08-24 2023-03-02 南京明德新药研发有限公司 咪唑并环类化合物及其应用
CN115850296A (zh) * 2021-12-03 2023-03-28 杭州先为达生物科技有限公司 一种噻吩并咪唑类化合物的晶型及其制备方法
WO2023125896A1 (zh) * 2021-12-31 2023-07-06 海思科医药集团股份有限公司 一种glp-1激动剂中间体及其制备方法及在医药中的用途
WO2023130878A1 (zh) * 2022-01-10 2023-07-13 海思科医药集团股份有限公司 一种glp-1激动剂盐及其晶型及在医药上的应用
WO2023246833A1 (zh) * 2022-06-23 2023-12-28 西藏海思科制药有限公司 一种五并五元环衍生物的药物组合物及其在医药上的应用
TW202408504A (zh) * 2022-06-23 2024-03-01 大陸商西藏海思科製藥有限公司 噻吩[2,3-d]咪唑類化合物的鹽及其晶型和在醫藥上的用途
WO2024102625A1 (en) 2022-11-11 2024-05-16 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists
WO2024107781A1 (en) 2022-11-16 2024-05-23 Eli Lilly And Company Glucagon-like peptide 1 receptor agonists

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020207474A1 (en) * 2019-04-12 2020-10-15 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
WO2021249492A1 (zh) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN113831337A (zh) * 2020-06-24 2021-12-24 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途
CN115698022A (zh) * 2020-06-04 2023-02-03 杭州先为达生物科技有限公司 五元杂芳并咪唑类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1594847A2 (en) * 2003-02-12 2005-11-16 Transtech Pharma, Inc. Substituted azole derivatives as therapeutic agents
PL3555064T3 (pl) * 2016-12-16 2023-03-06 Pfizer Inc. Agoności receptora GLP-1 i ich zastosowania
KR20210106447A (ko) * 2018-11-22 2021-08-30 치루 레고르 테라퓨틱스 인코포레이티드 Glp-1r 효능제 및 그의 용도
CN113801136B (zh) * 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
CN115850296A (zh) * 2021-12-03 2023-03-28 杭州先为达生物科技有限公司 一种噻吩并咪唑类化合物的晶型及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020207474A1 (en) * 2019-04-12 2020-10-15 Qilu Regor Therapeutics Inc. Glp-1r agonists and uses thereof
CN115698022A (zh) * 2020-06-04 2023-02-03 杭州先为达生物科技有限公司 五元杂芳并咪唑类化合物及其应用
WO2021249492A1 (zh) * 2020-06-10 2021-12-16 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN115697338A (zh) * 2020-06-10 2023-02-03 南京明德新药研发有限公司 甲基取代的苯并二噁唑类化合物及其应用
CN113831337A (zh) * 2020-06-24 2021-12-24 广州市恒诺康医药科技有限公司 Glp-1受体激动剂及其药物组合物和用途

Also Published As

Publication number Publication date
WO2022135572A1 (zh) 2022-06-30
TW202233181A (zh) 2022-09-01
ZA202306652B (en) 2024-03-27
EP4269399A1 (en) 2023-11-01
MX2023007569A (es) 2023-09-21
KR20230124956A (ko) 2023-08-28
JP2024500949A (ja) 2024-01-10
US20240124470A1 (en) 2024-04-18
EP4269399A4 (en) 2024-06-05
CN115667238B (zh) 2024-08-23
AU2021405918A9 (en) 2024-10-17
AU2021405918A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
CN115667238A (zh) 一种五并五元环衍生物及其在医药上的应用
CN109983007B (zh) 酰胺类衍生物抑制剂及其制备方法和应用
US12071433B2 (en) HMOX1 inducers
JP6949952B2 (ja) スピロ環化合物
CN114591296A (zh) 一种glp-1r激动剂及其在医药上的应用
WO2022111526A1 (zh) 一种苯环衍生物及其组合物和药学上的应用
WO2017061957A1 (en) Compounds for treatment of cancer and epigenetics
JPWO2016159082A1 (ja) ９員縮合環誘導体
AU2022300055A1 (en) Glp-1 receptor agonist and composition and use thereof
CN113999233A (zh) 一种btk抑制剂环衍生物及其制备方法和药学上的应用
WO2023131167A1 (zh) 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
CN115340552A (zh) 一种杂环衍生物及其在医药上的应用
CA3203276A1 (en) Five-membered ring derivative and medical use thereof
WO2023246833A1 (zh) 一种五并五元环衍生物的药物组合物及其在医药上的应用
WO2024193640A1 (zh) Cdk抑制剂
WO2022223022A1 (zh) 一种并环杂环衍生物及其在医药上的应用
WO2023143384A1 (zh) 一种抑制或降解hpk1激酶的化合物及其在医药中的用途
CN115894479A (zh) 一种多环衍生物及其组合物和药学上的应用
TW202346294A (zh) 吡嗪酮衍生物及其在醫藥上的應用
CN114478366A (zh) 一种吡啶酮衍生物及其在医药上的应用
IL291418B2 (en) Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment
CN118047793A (zh) 一种吡啶衍生物及其应用
CN118255746A (zh) 选择性cdk12/13抑制剂及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084438

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20231116

Address after: 856099 Xingfu Jiayuan Economic Development Zone, Gyerba, Nedong District, Shannan City, Tibet Autonomous Region

Applicant after: Tibet Haisike Pharmaceutical Co.,Ltd.

Address before: 611130 Sichuan Chengdu Wenjiang District Science and Technology Park cross strait Bailey Road 136

Applicant before: SICHUAN HAISCO PHARMACEUTICAL Co.,Ltd.

GR01 Patent grant
GR01 Patent grant